(HealthDay News) — A humanized antibody prevents thrombosis without increasing bleeding in extracorporeal circulation in animal models, according to a study published in the February 5 issue of Science Translational Medicine.
Magnus Larsson, from the Karolinska Institutet in Stockholm, and colleagues used phage display to screen for antibodies against activated factor XII (FXIIa) that would prevent thrombosis without increasing bleeding.
The researchers found that the recombinant fully human antibody 3F7 could block coagulation and prevent thrombosis in mice and rabbits. In rabbits, 3F7 was as effective as heparin in preventing thrombosis and fibrin deposition in an extracorporeal membrane oxygenation cardiopulmonary bypass system. However, only 3F7 did not increase bleeding.
“These data establish that targeting of FXIIa is a safe mode of thromboprotection in bypass systems, and provide a clinically relevant anticoagulation strategy that is not complicated by excess bleeding,” Larsson and colleagues conclude.
Several authors are employees of CSL. One author is an inventor on a patent application covering the use of FXII as an antithrombotic target.